Akebia Therapeutics Inc
Research Akebia Therapeutics Inc (AKBA) on Bullrun: market cap USD 260.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAKBA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 260.33M
- Financial periodQ2 2026
- RevenueUSD 49.13M
- Net income-USD 8.91M
- Free cash flow-USD 554.00K
- Gross margin78.8%
Valuation Snapshot
latest market cap is USD 260.33M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 236.20M | -USD 5.30M | USD 67.70M | 83.3% | -0.02 | USD 184.84M | USD 48.25M | USD 32.61M |
| FY2024 | USD 160.18M | -USD 69.40M | -USD 40.69M | 60.6% | -0.33 | USD 51.87M | USD 38.69M | -USD 49.19M |
| FY2023 | USD 194.62M | -USD 51.90M | -USD 23.38M | 61.9% | -0.28 | USD 42.93M | USD 34.68M | -USD 30.58M |
| FY2022 | USD 292.48M | -USD 94.20M | -USD 73.27M | 70.7% | -0.52 | USD 90.47M | USD 66.08M | USD 5.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 260.33M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 427.33M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 427.21M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 233.60M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 106.70M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 400.02M | n/a | n/a | n/a |
About Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Akebia Therapeutics Inc's market cap?
Akebia Therapeutics Inc's market capitalization is USD 260.33M.
What does Akebia Therapeutics Inc do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.